Cambrex has revealed that it is expanding its solid form screening and crystallization process development facility in Edinburgh, Scotland.
Cambrex has revealed that it is expanding its solid form screening and crystallization process development facility in Edinburgh, Scotland to add supplementary laboratory space that will double the current footprint.
In a July 30, 2019 press release, the company revealed that the expansion will enable recruitment of 40 more scientists, adding to the already employed 50, and will also allow for potential future growth. The expanded facility fit out is expected to commence late August 2019, and the company has set a target time for completion as the end of the year.
“This strategic expansion, the increase in headcount, and the investment in new equipment will enable us to serve more customers in the solid-state screening market,” commented Mark Benger, Edinburgh site director, Cambrex. “We have increasingly been asked by clients for additional services such as larger-scale crystallization, and we will now be able to provide these as well as adding greater efficiency and capacity at the Edinburgh site.”
The expanded facility will feature additional instruments and reactors for large-scale crystallization studies and solid form screening capabilities. Furthermore, the company states that plans are in place for the installation of new ultra-performance liquid chromatography and gas chromatography instruments, as well as additional process analytical technology tools.
Source: Cambrex
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.